Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

NCT00798720 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non Small Cell Lung

Interventions

DRUG: vorinostat
DRUG: bortezomib

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]
[object Object]